NeuroOne (NMTC) gets Nasdaq bid-price extension to May 4, 2026

NeuroOne Medical Technologies (NMTC) received a Nasdaq extension to regain compliance with the Nasdaq Capital Market’s Minimum Bid Price Requirement of $1.00 per share.

Rhea-AI Filing Summary

NeuroOne Medical Technologies (NMTC) received a Nasdaq extension to regain compliance with the Nasdaq Capital Market’s Minimum Bid Price Requirement of $1.00 per share. Nasdaq granted a 180-day extension through May 4, 2026.

The extension has no immediate effect on the company’s listing; NMTC’s common stock remains fully listed on the Nasdaq Capital Market. The company previously had until November 3, 2025 to cure the deficiency and has not yet regained compliance.

NeuroOne plans to continue monitoring the closing bid price and to seek compliance within the extension period. If compliance is not regained by the new deadline, Nasdaq may notify the company that its common stock is subject to delisting, and the company would have the right to appeal to a Nasdaq Hearing Panel.

Insights

Listing compliance analyst

NMTC has until May 4, 2026 to meet the $1.00 bid rule.

Nasdaq granted NeuroOne a 180-day extension to satisfy the Minimum Bid Price Requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. The stock remains listed during this period, so trading status is unchanged by the notice.

The outcome hinges on the company’s ability to have its closing bid at or above the threshold for the required duration, which depends on market pricing. The company states it will continue monitoring its closing bid and seek to regain compliance.

If compliance isn’t achieved by May 4, 2026, Nasdaq may move to delist; the company could appeal to a Hearing Panel. Actual impact will depend on whether compliance is achieved before the deadline.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

What did Nasdaq grant NeuroOne Medical Technologies (NMTC)?

Nasdaq granted a 180-day extension to regain compliance with the $1.00 Minimum Bid Price Requirement.

What is the new deadline for NMTC to meet the minimum bid price?

The new deadline to regain compliance is May 4, 2026.

Does the extension affect NMTC’s current Nasdaq listing status?

No. The notice has no immediate effect; NMTC’s listing remains fully effective on the Nasdaq Capital Market.

What is the specific Nasdaq requirement NMTC must meet?

NMTC must maintain a minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).

What happens if NMTC does not regain compliance by the deadline?

Nasdaq may notify the company that its common stock is subject to delisting, and the company may appeal to a Nasdaq Hearing Panel.

What was NMTC’s prior compliance window before the extension?

The prior cure period ran until November 3, 2025.

What action does NMTC plan to take during the extension period?

The company will continue to monitor the closing bid price and seek to regain compliance within the extension period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 08:54 AM Learn about SEC filing dates

false 0001500198 0001500198 2025-11-04 2025-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 4, 2025

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-40439		27-0863354
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 4, 2025, NeuroOne Medical Technologies Corporation (the “Company”) received a letter (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company a 180-day extension, until May 4, 2026 (the “Extension Period”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“Common Stock”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective.

As previously disclosed in the Company’s Current Report on Form 8-K, filed on May 9, 2025, the Company received notice from Nasdaq that the Company was not in compliance with the Minimum Bid Price Requirement for a period of 30 consecutive business days (the “Initial Notice”). As provided in the Initial Notice, the Company had a 180-day period, until November 3, 2025, to regain compliance with the Minimum Bid Price Requirement. As of the date of this Report, the Company has not yet regained compliance with the Minimum Bid Price Requirement, and instead advised Nasdaq of its intent to cure the deficiency within the Extension Period.

The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with the Minimum Bid Price Requirement within the Extension Period. If the Company does not regain compliance with the Minimum Bid Price Requirement within the Extension Period, Nasdaq will provide written notification to the Company that its Common Stock will be subject to delisting, at which time the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearing Panel (the “Panel”). There can be no assurance that, if the Company does need to appeal a Nasdaq delisting determination to the Panel, that such appeal would be successful.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: November 5, 2025
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

2